novel ultra-sensitive mrd profiling tool predicts outcomes in dlbcl after frontline treatment
Published 1 year ago • 75 plays • Length 1:28Download video MP4
Download video MP3
Similar videos
-
2:35
an update on mrd assessment and novel techniques used in the treatment of hematological malignancies
-
12:00
hipec: a novel treatment for advanced abdominal cancers
-
12:00
hipec: a novel treatment for advanced abdominal cancers
-
1:38
using pet to predict failure to salvage therapy in patients with dlbcl
-
12:05
how to clean/change biobase hematology valves
-
2:02
nahtmaterial vicryl
-
5:23
set up installation
-
6:33
mrd as a tool to discontinue therapy in mm?
-
2:19
anbal-cel: updated results from phase i study of novel cd19-targeting car-t therapy
-
2:38
zuma-1 & scholar-1: comparison of outcomes in refractory dlbcl
-
0:42
targeted therapies for dlbcl treatment
-
1:19
the impact of mrd status by clonoseq® in patients with mcl, dlbcl & fl treated with car-t therapy
-
1:46
phase ii study of acalabrutinib plus rice in r/r dlbcl
-
1:13
mrd: a valuable tool in cll
-
3:35
outcomes of patients with dlbcl who relapse early following r-ice chemoimmunotherapy
-
2:29
epitope editing enables the use of novel immunotherapies for aml
-
2:22
improve study: mrd assessment as an endpoint to define treatment length and intensity in cll
-
31:06
novel biomarker module six - result interpretation
-
2:53
autohct in dlbcl in the car-t era
-
1:58
ash highlights: glofitamab in dlbcl & pirtobrutinib and epcoritamab in richter's transformation
-
3:26
miracle study: using an mrd-guided strategy to direct treatment duration in previously untreated cll